论文部分内容阅读
目的观察胰岛素增敏剂马来酸罗格列酮(RSG)对2型糖尿病(T2DM)患者血压(BP)的影响。方法68例初诊T2DM患者,未服用任何降压药物,分为BP正常(DMN)和合并有高血压(DMH)两组,均日服RSG4mg,疗程12周。分析BP下降情况及影响因素。结果RSG治疗12周后,(1)DMN组收缩压(SBP)平均降低4mmHg,舒张压(DBP)平均降低3mmHg,治疗前后的差异无统计学意义(P均>0.05);DMH组中SBP平均降低9mmHg,DBP平均降低6mmHg,治疗前后的差异有统计学意义(P均<0.01)。(2)DMH组中基线BP水平较高患者可引起较大幅度的降低(P<0.05)。(3)T2DM患者治疗前后SBP、DBP改变均与HOMA-IR有明显相关性。结论RSG对并发高血压的T2DM患者在改善IR的同时,血压也明显降低。
Objective To observe the effect of rosiglitazone maleate (RSG), an insulin sensitizer, on blood pressure (BP) in type 2 diabetes mellitus (T2DM). Methods Sixty-eight newly diagnosed T2DM patients without any antihypertensive drugs were divided into normal BP (DMN) group and high blood pressure (DMH) group with RSG 4 mg daily for 12 weeks. Analysis of BP decline and influencing factors. Results After 12 weeks of RSG treatment, (1) SBP decreased by 4 mmHg and DBP decreased by 3 mmHg on average in DMN group (P> 0.05). The mean SBP in DMH group Reduce 9mmHg, DBP average reduction of 6mmHg, before and after treatment were statistically significant (P all <0.01). (2) Patients with higher baseline BP levels in DMH group could cause more significant decrease (P <0.05). (3) The changes of SBP and DBP before and after treatment in T2DM patients were significantly correlated with HOMA-IR. Conclusions RSG improves blood pressure in T2DM patients with hypertension as well as blood pressure.